Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C

Samankaltaisia teoksia

• Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT
  Tekijä: Cooke, GS, et al.
  Julkaistu: (2021)
• HCV-specific T-CELL responses of acutely HCV infected individuals with and without HIV.
  Tekijä: Danta, M, et al.
  Julkaistu: (2005)
• Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus
  Tekijä: Sy, A, et al.
  Julkaistu: (2023)
• The design and statistical aspects of VIETNARMS: A strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam
  Tekijä: McCabe, L, et al.
  Julkaistu: (2020)
• Rise in alanine aminotransferase after HCV treatment is a highly sensitive screen for treatment failure
  Tekijä: Flower, B, et al.
  Julkaistu: (2023)